相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Alternative metrics for assessing clinical benefit with immunotherapy in oncology
E. Chan et al.
ONCOIMMUNOLOGY (2019)
Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?
Hans-Georg Eichler et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials
Shirley Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia
Jonathan Webster et al.
CLINICAL THERAPEUTICS (2019)
Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards
Giles Monnickendam et al.
VALUE IN HEALTH (2019)
Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment
Concetta Elisa Onesti et al.
JOURNAL OF THORACIC DISEASE (2019)
Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review
Sebastien Branchoux et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
Mario J. N. M. Ouwens et al.
PHARMACOECONOMICS (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study
Ash Bullement et al.
VALUE IN HEALTH (2019)
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Ash Bullement et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Dawn Lee et al.
PHARMACOECONOMICS-OPEN (2019)
Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
Amr Makady et al.
PHARMACOECONOMICS (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
Sirisha L. Mushti et al.
CLINICAL CANCER RESEARCH (2018)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pages et al.
LANCET (2018)
Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy
Brian M. Alexander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
THE IMPACT OF RESPONSE AT A LANDMARK ON OVERALL SURVIVAL: IMPLICATIONS FOR THE ECONOMIC EVALUATION OF THE VALUE OF IMMUNO-ONCOLOGY (I-O) TREATMENT IN NON-SMALL CELL LUNG CANCER (NSCLC)
I Santi et al.
VALUE IN HEALTH (2018)
Do immune checkpoint inhibitors need new studies methodology?
Roberto Ferrara et al.
JOURNAL OF THORACIC DISEASE (2018)
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
Yingming Zhu et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Immuno-Oncology: Emerging Targets and Combination Therapies
Henry T. Marshall et al.
FRONTIERS IN ONCOLOGY (2018)
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Lawrence Blonde et al.
ADVANCES IN THERAPY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
EXTRAPOLATION OF SURVIVAL CURVES USING EXTERNAL INFORMATION: IMPLEMENTATION OF GUYOT'S METHOD IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA
H. Cawston et al.
VALUE IN HEALTH (2018)
THE IMPACT OF LANDMARK RESPONSE ON OVERALL SURVIVAL: IMPLICATIONS FOR THE ECONOMIC EVALUATION OF IMMUNE-THERAPY (I-O) TREATMENT IN SMALL CELL LUNG CANCER (SCLC)
I Santi et al.
VALUE IN HEALTH (2018)
WHAT IS THE VALUE OF REAL WORLD EVIDENCE IN ONCOLOGY IN HTA APPRAISALS IN ENGLAND, FRANCE, CANADA AND AUSTRALIA?
T. Ng et al.
VALUE IN HEALTH (2018)
The search for surrogate endpoints for immunotherapy trials
Marc Buyse et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making
Vaibhav B. Katkade et al.
JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2018)
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Antje Hoering et al.
FUTURE ONCOLOGY (2017)
Pembrolizumab in advanced head and neck cancer
Vicki Brower
LANCET ONCOLOGY (2017)
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
Eddie Gibson et al.
PHARMACOECONOMICS (2017)
Immunotherapy and patients treated for cancer with microsatellite instability
Raphael Colle et al.
BULLETIN DU CANCER (2017)
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review
Paola Queirolo et al.
CANCER TREATMENT REVIEWS (2017)
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Robert Kemp et al.
BMC MEDICINE (2017)
Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation
Duane Schulthess et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2016)
Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets
Anton Bespalov et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence
Christina Giannopoulou et al.
PHARMACOECONOMICS (2015)
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
Nigel Fleeman et al.
PHARMACOECONOMICS (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
David McDermott et al.
CANCER TREATMENT REVIEWS (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
Jerome Galon et al.
JOURNAL OF PATHOLOGY (2014)
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide
Nicholas R. Latimer
MEDICAL DECISION MAKING (2013)
Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
Sophie Beale et al.
PHARMACOECONOMICS (2013)
Statistical issues and challenges in immuno-oncology
Tai-Tsang Chen
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Immune Score as a New Possible Approach for the Classification of Cancer
Jerome Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Claus Garbe et al.
ONCOLOGIST (2011)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Estimating the cure fraction in population-based cancer studies by using finite mixture models
P. C. Lambert et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Further development of flexible parametric models for survival analysis
Paul C. Lambert et al.
STATA JOURNAL (2009)
Estimating and modeling the cure fraction in population-based cancer survival analysis
Paul C. Lambert et al.
BIOSTATISTICS (2007)
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects
P Royston et al.
STATISTICS IN MEDICINE (2002)
分享论文
